Table 1 Characteristics of the patients
| Â | All patients* | N | C |
|---|---|---|---|
Number of patients | 110 | 47 | 63 |
Females, n (%) | 40 (36.4) | 18 (38.3) | 22 (34.9) |
Age, years, mean ± SD | 51.7 ± 1.3 | 53.0 ± 1.3 | 49.6 ± 1.3 |
Schooling | |||
 Primary school, n (%) | 8 (7.3) | 4 (8.5) | 4 (6.3) |
 Middle school, n (%) | 45 (40.9) | 18 (38.3) | 27 (42.9) |
 Secondary school, n (%) | 36 (32.7) | 17 (36.2) | 19 (30.2) |
 University, n (%) | 21 (19.1) | 8 (17) | 13 (20.6) |
Social status | |||
 Living with parents and family, n (%) | 15 (13.6) | 6 (12.8) | 9 (14.3) |
 Living alone, n (%) | 16 (14.5) | 7 (14.9) | 9 (14.3) |
 Living with partner and family, n (%) | 71 (64.5) | 29 (61.7) | 42 (66.7) |
 Others, n (%) | 8 (7.3) | 5 (10.6) | 3 (4.8) |
Full- or part-time employed, n (%) | 76 (69.1) | 29 (61.7) | 47 (74.6) |
Smoking, current, n (%) | 17 (15.5) | 5 (10.6) | 12 (19) |
HLA-B27 positivity, n (%) | 58 (52.7) | 22 (46.8) | 36 (57.1) |
Psoriasis, n (%) | 58 (50.7) | 26 (55.3) | 32 (50.8) |
Uveitis, n (%) | 7 (6.4) | 5 (10.6) | 2 (3.2) |
Disease duration (years), mean ± SD | 15.3 ± 9.7 | 15.7 ± 10 | 15 ± 9.5 |
Mechanism of action of current b/tsDMARD | |||
 TNF inhibitors, n (%) | 85 (77.3) | 40 (85.1) | 45 (71.4) |
 IL-12/23 inhibitors, n (%) | 9 (8.2) | 1 (2.1) | 8 (12.7) |
 IL-17 inhibitors, n (%) | 14 (12.7) | 6 (12.8) | 8 (12.7) |
 PDE4 inhibitors, n (%) | 2 (1.8) | 0 (0) | 2 (3.2) |
Duration of b/tsDMARD treatment overall, years, mean ± SD | 5 ± 4.1 | 5.8 ± 4.5 | 4.5 ± 3.8 |
Low-dose b/tsDMARD treatment, n (%) | 28 (25.5) | 11 (23.4) | 17 (27) |
b/tsDMARD naïve patients, n (%) | 81 (73.6) | 37 (78.7) | 44 (69.8) |
No. of b/tsDMARD treatments, mean ± SD | 1.5 ± 0.9 | 1.3 ± 0.7 | 1.6 ± 1.1 |
Steroid, n (%) | 9 (8.2) | 1 (2.1) | 8 (12.7) |
NSAID, n (%) | 76 (69.1) | 30 (63.8) | 46 (73) |
csDMARD, n (%) | 14 (12.7) | 5 (10.6) | 9 (14.3) |
Concomitant treatments, n (%) | 62 (56.4) | 27 (57.4) | 35 (55.6) |
Distance from clinic, km, mean ± SD | 36.1 ± 47.2 | 31.1 ± 34.2 | 39.7 ± 54.9 |